Physician profile
Mark Klein
NPI 1982686390
$8,314.98
in general payments reported to CMS, 2019-2025
47 companies · $859 in 2025
The $859 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,437 · 2020: $1,496 · 2021: $1,367 · 2022: $1,052 · 2023: $1,313 · 2024: $790 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,944 · Entertainment: $19.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,943.78 |
| Entertainment | $19.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,636.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $818.88 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.49 | 2019-2024 | Jardiance |
| Pfizer INC. | $590.76 | 2019-2021 | |
| Abbvie INC. | $554.63 | 2021-2025 | |
| Glaxosmithkline, LLC. | $508.83 | 2019-2024 | Shingrix, Menveo, Bexsero |
| Lilly USA, LLC | $502.91 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $429.54 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $310.56 | 2019-2023 | Steglatro, Belsomra, Steglujan |
| Sanofi-Aventis U.S. LLC | $288.27 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $241.94 | 2024-2025 | Voquezna |
| Exact Sciences Corporation | $166.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Merz North America, INC. | $145.58 | 2023 | Xeomin |
| Mylan Specialty L.P. | $138.11 | 2019-2022 | |
| Dexcom, INC. | $127.85 | 2022-2023 | Dexcom G6 Transmitter |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Klein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.